Haleon (HLN) Stock
Key stats
- Market cap
- $39.94B
- Price / Earnings ratio
- 18.0x
- EPS (TTM)
- $0.50
- Volume
- Loading
- 52-week high
- $11.28
- 52-week low
- $8.38
- Dividend yield
- 2.07%
- Dividend amount (latest)
- $0.12
Source: third-party data provider, as of November 13, 2026
Compare with HLN
Recent news

ASAIY or HLN: Which Is the Better Value Stock Right Now?
ASAIY or HLN: Which Is the Better Value Stock Right Now?
HLN

What Haleon (HLN) Said on Its Q3 Earnings Call
What Haleon (HLN) Said on Its Q3 Earnings Call
HLN

Haleon CEO warns staff of 'difficult choices' ahead after sales miss, memo says
Haleon CEO warns staff of 'difficult choices' ahead after sales miss, memo says
HLN

Sensodyne maker Haleon cuts revenue growth forecast on weak flu season, China disruption
Sensodyne maker Haleon cuts revenue growth forecast on weak flu season, China disruption
HLN
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 44.44
- MACD 12/26/9
- -0.14
- EMA 9 of MACD
- -0.09
- MACD histogram
- -0.06
- SMA 50
- $9.37
- Price below SMA 50
- EMA 50
- $9.42
- Price below EMA 50
- SMA 200
- $9.72
- Price below SMA 200
- EMA 200
- $9.66
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The company reported results on Jul 31 2025. The market has no earnings per share expectations for this quarter.
Source: third-party data provider
Latest news

ASAIY or HLN: Which Is the Better Value Stock Right Now?
ASAIY or HLN: Which Is the Better Value Stock Right Now?
HLN

What Haleon (HLN) Said on Its Q3 Earnings Call
What Haleon (HLN) Said on Its Q3 Earnings Call
HLN

Haleon CEO warns staff of 'difficult choices' ahead after sales miss, memo says
Haleon CEO warns staff of 'difficult choices' ahead after sales miss, memo says
HLN

Sensodyne maker Haleon cuts revenue growth forecast on weak flu season, China disruption
Sensodyne maker Haleon cuts revenue growth forecast on weak flu season, China disruption
HLN

UBS says early flu pick-up could lift 2027 earnings at Reckitt and Haleon
UBS says early flu pick-up could lift 2027 earnings at Reckitt and Haleon
HLN

Goldman Sachs Top European Stock Picks Have a Hidden Perk for Income Investors
Goldman Sachs Top European Stock Picks Have a Hidden Perk for Income Investors
HLN

Unilever on JP Morgan positive watch as Haleon faces caution
Unilever on JP Morgan positive watch as Haleon faces caution
HLN

LCUT vs. HLN: Which Stock Is the Better Value Option?
LCUT vs. HLN: Which Stock Is the Better Value Option?
HLN

Haleon tipped to cut sales growth guidance as cough and cold season clouds outlook
Haleon tipped to cut sales growth guidance as cough and cold season clouds outlook
HLN

Deutsche Bank stays bearish on Haleon as growth headwinds mount
Deutsche Bank stays bearish on Haleon as growth headwinds mount
HLN
News tone: automated (AI) classification of the article's content, not a price prediction.
About Haleon
Haleon is a world-leading company focused on everyday health. It is the new name of GSK’s spun out Consumer Healthcare division. Haleon's leading brands are built on science, innovation and human understanding and are trusted by millions of consumers globally. Its current portfolio includes various international brands including Sensodyne, Voltaren and Panadol.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Brian James McNamara | CEO & Executive Director | 1966 |
| Ms. Dawn Amanda Allen | CFO & Director | 1968 |
| Ms. Claire Dickson | Chief Digital & Technology Officer | — |
| Ms. Joanne Russell | Head of Investor Relations | — |
| Mr. Adrian Charles Morris | General Counsel | 1967 |
| Ms. Tamara Jane Rogers | Chief Marketing Officer | 1968 |
| Ms. Line De Decker | Chief Human Resources Officer | 1974 |
| Mr. Filippo Lanzi | President of EMEA & LatAm | — |
| Mr. Keith Choy | President of Asia Pacific | 1969 |
| Mr. Bjorn Timelin | Head of Strategy | — |
Fundamentals
Valuation
Profitability
Trading
Dividend
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 44.44
- MACD 12/26/9
- -0.14
- EMA 9 of MACD
- -0.09
- MACD histogram
- -0.06
- SMA 50
- $9.37
- Price below SMA 50
- EMA 50
- $9.42
- Price below EMA 50
- SMA 200
- $9.72
- Price below SMA 200
- EMA 200
- $9.66
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022 | -6.3 | -18.9 | +5.0 | -0.3 | +12.2 | +13.0 | ||||||
| 2023 | +2.1 | -1.0 | +2.8 | +8.6 | -9.0 | +2.8 | +7.6 | -3.9 | +2.8 | -2.2 | +5.2 | -4.1 |
| 2024 | -0.4 | +1.9 | +0.5 | +2.3 | +1.1 | -2.5 | +10.0 | +9.1 | +4.1 | -9.4 | -0.7 | -1.3 |
| 2025 | +0.3 | +7.4 | -2.7 | -0.3 | +9.9 | -9.1 | -8.9 | +1.4 | -8.1 | +2.9 | +4.3 | +3.2 |
| 2026 | +4.7 | +4.8 | -7.9 | -7.3 | -3.4 | +5.5 | +5.0 | +2.3 | -10.6 | -0.7 | +3.9 |
Corporate actions
Upcoming
No upcoming corporate actions for HLN



